Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury

Martin Oudega, Owen Y. Chao, Donna Avison, Roderick T. Bronson, William J. Buchser, Andres Hurtado, Barbara Grimpe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.

Original languageEnglish
Pages (from-to)170-179
Number of pages10
JournalExperimental Neurology
Volume237
Issue number1
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Catalytic DNA
Spinal Cord Injuries
Messenger RNA
Cicatrix
Spinal Cord Regeneration
Contusions
Neuralgia
Proteoglycans
Enzymes
Growth
Glycosaminoglycans
Intravenous Administration
Toxicology
Axons
Regeneration
Quality of Life
DNA
Wounds and Injuries
Therapeutics
UDP xylose-protein xylosyltransferase

Keywords

  • Chondroitin sulfate proteoglycans
  • DNA enzyme
  • Functional recovery
  • Glial scar
  • Neurotherapeutics
  • Regeneration
  • Spinal cord injury

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury. / Oudega, Martin; Chao, Owen Y.; Avison, Donna; Bronson, Roderick T.; Buchser, William J.; Hurtado, Andres; Grimpe, Barbara.

In: Experimental Neurology, Vol. 237, No. 1, 01.09.2012, p. 170-179.

Research output: Contribution to journalArticle

Oudega, Martin ; Chao, Owen Y. ; Avison, Donna ; Bronson, Roderick T. ; Buchser, William J. ; Hurtado, Andres ; Grimpe, Barbara. / Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury. In: Experimental Neurology. 2012 ; Vol. 237, No. 1. pp. 170-179.
@article{6e45013577064df9b107210c47f10cd3,
title = "Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury",
abstract = "After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.",
keywords = "Chondroitin sulfate proteoglycans, DNA enzyme, Functional recovery, Glial scar, Neurotherapeutics, Regeneration, Spinal cord injury",
author = "Martin Oudega and Chao, {Owen Y.} and Donna Avison and Bronson, {Roderick T.} and Buchser, {William J.} and Andres Hurtado and Barbara Grimpe",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.expneurol.2012.06.006",
language = "English",
volume = "237",
pages = "170--179",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Systemic administration of a deoxyribozyme to xylosyltransferase-1 mRNA promotes recovery after a spinal cord contusion injury

AU - Oudega, Martin

AU - Chao, Owen Y.

AU - Avison, Donna

AU - Bronson, Roderick T.

AU - Buchser, William J.

AU - Hurtado, Andres

AU - Grimpe, Barbara

PY - 2012/9/1

Y1 - 2012/9/1

N2 - After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.

AB - After spinal cord injury, proteoglycans with growth-inhibitory glycosaminoglycan (GAG-) side chains in scar tissue limit spontaneous axonal sprouting/regeneration. Interventions that reduce scar-related inhibition facilitate an axonal growth response and possibly plasticity-based spinal cord repair. Xylosyltransferase-1 (XT-1) is the enzyme that initiates GAG-chain formation. We investigated whether intravenous administration of a deoxyribozyme (DNA enzyme) to XT-1 mRNA (DNAXT-1as) would elicit plasticity after a clinically relevant contusion of the spinal cord in adult rats. Our data showed that systemic DNAXT-1as administration resulted in a significant increase in sensorimotor function and serotonergic axon presence caudal to the injury. DNAXT1as treatment did not cause pathological or toxicological side effects. Importantly, intravenous delivery of DNAXT-1as did not exacerbate contusion-induced neuropathic pain. Collectively, our data demonstrate that DNAXT-1as is a safe neurotherapeutic, which holds promise to become an integral component of therapies that aim to improve the quality of life of persons with spinal cord injury.

KW - Chondroitin sulfate proteoglycans

KW - DNA enzyme

KW - Functional recovery

KW - Glial scar

KW - Neurotherapeutics

KW - Regeneration

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84863814693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863814693&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2012.06.006

DO - 10.1016/j.expneurol.2012.06.006

M3 - Article

C2 - 22721770

AN - SCOPUS:84863814693

VL - 237

SP - 170

EP - 179

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -